Barrx™ 360 Express RFA Balloon Catheter
Barrx™ 360 RFA Balloon Catheters
Barrx™ Channel RFA Endoscopic Catheter
Barrx™ RFA Focal Catheters
Barrx™ Radiofrequency Ablation System
Barrx™ RFA Accessories
We offer a comprehensive portfolio of radiofrequency ablation solutions to treat Barrett's esophagus and other GI tract diseases.([FOOTNOTE=Phoa KN, van Vilsteren FG, Pouw RE, et al. Radiofrequency ablation in Barrett's esophagus with confirmed low-grade dysplasia: interim results of a European multicenter randomized controlled trial (SURF). Gastroenterology. 2013; 144:S-187.],[ANCHOR=],[LINK=]),([FOOTNOTE=Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esphagus with dysplasia. N Engl J Med. 2009 May 28;360(22):2277-88.],[ANCHOR=],[LINK=]),([FOOTNOTE=van Vilsteren FG, Pouw RE, Seewald S, Alvarez HL, Sondermeijer CM, Visser M, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's esophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011; 60:765-73.],[ANCHOR=],[LINK=]),([FOOTNOTE=Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781-9],[ANCHOR=],[LINK=]),([FOOTNOTE=Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013 Jul; 145(1):96-104.],[ANCHOR=],[LINK=]),([FOOTNOTE=Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. AM J Gastroenterol. 2011;106:1899-908.],[ANCHOR=],[LINK=]) With focal and circumferential catheters, plus advanced features designed to increase procedural efficiency, these innovations provide the flexibility needed to meet the unique needs of each patient.
The Barrx™ channel RFA endoscopic catheter offers the same ablation capabilities as the widely accepted focal and balloon catheters, delivering controlled depth of coagulation for Barrett’s esophagus and other bleeding and non-bleeding conditions of the GI tract.([FOOTNOTE=Based on internal test report P/N V-0234-02 (A), Channel design verification testing. GI Solutions, data on file.],[ANCHOR=],[LINK=]) ,([FOOTNOTE=Based on internal test report L-0190-02 (A), The Bergman animal study report. GI Solutions, data on file.],[ANCHOR=],[LINK=]) ,([FOOTNOTE=Barrx™ channel RFA endoscopic catheter Instructions for Use (IFU).],[ANCHOR=],[LINK=])
Read this Clinical Trial summary investigating whether endoscopic radiofrequency ablation (RFA) could decrease the rate of neoplastic progression in patients with confirmed low-grade dysplasia (LGD).
Esophageal cancer has the highest incidence in the UK, Netherlands and Ireland. Increase in population mortality for esophageal cancer is predicted to increase over the next 10 years.([FOOTNOTE=Farthing, M., Roberts, S.E., Samuel, D.G., Williams, J.G., Thorne, K., Morrison-Rees, S., John, A. and Akbari, A. (2014) ‘Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe’, United European Gastroenterology Journal, 2(6), pp. 539–543. doi: 10.1177/2050640614554154],[ANCHOR=],[LINK=])